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1  | INTRODUC TION
Amelogenesis is the production of dental enamel, the hardest struc‐
ture produced by the human body. The process is comprised of two 
major stages: the secretion and maturation stages. These result in 
an acellular, high‐strength hydroxyapatite structure with a distinct 
latticelike organization, designed to maintain function over a lifetime 
without the need for cellular repair (Robinson et al., 2000).
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Abstract
Objectives: Variants in DLX3 cause tricho‐dento‐osseous syndrome (TDO, MIM 
#190320), a systemic condition with hair, nail and bony changes, taurodontism and 
amelogenesis imperfecta (AI), inherited in an autosomal dominant fashion. Different 
variants found within this gene are associated with different phenotypic presenta‐
tions. To date, six different DLX3 variants have been reported in TDO. The aim of this 
paper was to explore and discuss three recently uncovered new variants in DLX3.
Subjects and Methods: Whole‐exome sequencing identified a new DLX3 variant in 
one family, recruited as part of an ongoing study of genetic variants associated with 
AI. Targeted clinical exome sequencing of two further families revealed another new 
variant of DLX3 and complete heterozygous deletion of DLX3. For all three families, 
the phenotypes were shown to consist of AI and taurodontism, together with other 
attenuated features of TDO.
Results: c.574delG p.(E192Rfs*66), c.476G>T (p.R159L) and a heterozygous deletion 
of the entire DLX3 coding region were identified in our families.
Conclusion: These previously unreported variants add to the growing literature sur‐
rounding AI, allowing for more accurate genetic testing and better understanding of 
the associated clinical consequences.
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Amelogenesis imperfecta (AI) is a group of heterogeneous ge‐
netic conditions characterized by abnormal or absent enamel pro‐
duction. AI arises due to genetic changes affecting the secretory 
and/or maturation stages. Unlike many environmental causes of ab‐
normal enamel, AI affects both the primary and secondary dentition. 
The severity of the condition is highly variable. AI can be divided into 
two major groups: hypoplastic (due to inadequate enamel volume) 
or hypomineralized (due to inadequate mineralization). However, 
mixed presentations exist and there is a spectrum of phenotypes. 
The prevalence of AI is reported to be between 1/700 and 1/14,000, 
depending upon the population studied (Bäckman & Holm, 1986; 
Witkop & Sauk, 1976). X‐linked, autosomal dominant and autosomal 
recessive inheritance patterns have all been reported for AI (Lacruz, 
Habelitz, Wright, & Paine, 2017; Smith et al., 2017).
AI may also be part of syndromic conditions such as tricho‐dento‐
osseous syndrome (TDO) (MIM #190320, Jorgenson & Warson, 
1973). TDO is a rare, autosomal dominant systemic genetic disease 
resulting from heterozygous mutations in DLX3 (distal‐less homeo‐
box 3) and has an unknown incidence rate. The majority of published 
cases were identified in the United States, specifically in Virginia, 
Tennessee and North Carolina (Price, Bowden, Wright, Pettenati, & 
Hart, 1998). All of the individuals reported to date presented with 
taurodontism and enamel hypoplasia. Robinson and Miller (1966) 
reported that the hair of affected individuals is classically coarse, 
kinky/curly, brittle and rough, with profuse shedding. This usually 
normalizes with age. Skeletal abnormalities within the head and neck 
have also been associated with TDO, including a lack of mastoid 
pneumatization, increased thickness of the cranial bones, increased 
bone density and a shortened mandibular ramus (Crawford & 
Aldred, 1990). The thickening of the bone in TDO may be of concern 
with regard to the increased risk of fracture or macrocephaly (Al‐
Batayneh, 2012; Shapiro, Quattromani, Jorgenson, Young, & Opitz, 
1983). However, Hart et al. (1997) stated that the bone changes are 
not associated with any pathology. Nails have also been reported to 
show splitting and to break easily (Quattromani et al., 1983; Wright, 
Kula, Hall, Simmons, & Hart, 1997). Atopic dermatitis was also noted 
in one individual with TDO (Mayer, Baal, Litschauer‐Poursadrollah, 
Hemmer, & Jarisch, 2010).
The clinical abnormalities associated with TDO are usually iden‐
tified within the first year of life. Differentiating between TDO and 
amelogenesis imperfecta of the hypomaturation‐hypoplasia type 
with taurodontism (MIM #104510) can be difficult and is typically 
based upon other syndromic findings, such as kinky hair and bony 
changes. Both conditions have been associated with DLX3 muta‐
tions suggesting the two conditions may be part of the same syn‐
dromic spectrum (Dong et al., 2005). However, Price et al. (1999) 
and Crawford and Aldred (1990) considered the two syndromes dif‐
ferent entities. To address the controversy diagnosing TDO, Seow 
(1993) created criteria comprising generalized enamel defects; se‐
vere taurodontism affecting the mandibular first permanent molars; 
autosomal dominant inheritance; and at least one other feature (i.e., 
nail changes; bone sclerosis; or curly, kinky or wavy hair at a young 
age). However, because of the known clinical variations in the phe‐
notypes of TDO, these criteria are not widely used.
The first mutation identified in TDO was a 4‐bp deletion (Price 
et al., 1998), leading to a frameshift variant (c.571_574delGGGG, 
p.(G190delfs*66)). Since the original report by Price et al. (1998), five 
other mutations have been described within DLX3 (Dong et al., 2005; 
Harbuz et al., 2013; Li et al., 2015; Mayer et al., 2010; Nieminen et 
al., 2011) leading to attenuated versions of the disease (Wright et 
al., 2008).
This report presents two novel DLX3 variants and heterozygous 
deletion of DLX3 associated with AI. All families presented with AI 
prior to genetic testing. Subsequent to the identification of a DLX3 
variant in each family, affected individuals were reassessed clini‐
cally and were considered to have attenuated versions of TDO. We 
also report analysis of the hair phenotypes in family 1 and discuss 
the likely consequences of these newly identified mutations on the 
function of the DLX3 protein.
2  | MATERIAL S AND METHODS
2.1 | Patients
Eleven individuals from family 1, three individuals from family 2 
and one individual from family 3 (Figure 1) were recruited follow‐
ing informed consent in accordance with the principles outlined in 
F I G U R E  1   Pedigrees for families 1, 2 and 3. Probands whole‐
exome sequenced/targeted clinical‐exome sequenced marked with 
arrows. * indicates that the DNA was of insufficient quality and 
quantity to sequence. ●: Affected female, □: Unaffected male
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the Declaration of Helsinki and with local ethical approval by the 
National Research Ethics Service (South Yorkshire Research Ethics 
Committee ref: 13/YH/0028). For family 1, genomic DNA was ob‐
tained from saliva using Oragene® DNA Sample Collection kits 
(DNA Genotek, ON, Canada) according to the manufacturer’s in‐
structions. For families 2 and 3, genomic DNA was extracted from 
blood with the exception of individual III:1 (family 2), who deposited 
a buccal swab sample. Families 2 and 3 were screened as part of the 
recently developed NHS testing service for AI (available through the 
NHS UK Genetic Testing Network, https://ukgtn.nhs.uk/find‐a‐test/
search‐by‐disorder‐gene/details/6746/).
2.2 | Whole‐exome and targeted clinical exome 
sequencing and analysis
Genomic DNA from individual IV:1 from family 1 (marked with an 
arrow on the pedigree, Figure 1) was subjected to whole‐exome se‐
quencing (WES). Three micrograms of genomic DNA was processed 
using the SureSelect XT Library Prep and with the SureSelect Human 
All Exon v5 capture reagent according to the manufacturer’s proto‐
col (Agilent Technologies, Santa Clara, CA, USA). Sequencing was 
performed on an Illumina HiSeq 2500 (Illumina, San Diego, CA, USA) 
using a 100‐bp paired‐end protocol. The fastq files were aligned to 
F I G U R E  2   Clinical photographs and 
DNA sequencing electropherograms for 
families 1 and 2. (a, b) Clinical photographs 
of family 1 individual V:2. Note the 
carious lesions and thin, hypoplastic, 
pitted enamel. (c, d) Clinical photographs 
of family 2 individual III:1. Note 
worn, hypoplastic enamel. e‐f: Sanger 
sequencing electropherograms for family 
1; affected individual V2 (e), unaffected 
individual V:1 (f). (g, h) Sanger sequencing 
electropherograms for family 2; affected 
individual II:2 (g) and family 2 individual 
II:1 (h). Sanger sequencing reads for other 
members of family 1 are available in 
Supporting Information Figure S6 [Colour 
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the human reference genome (GRCh37) using the Burrows Wheeler 
aligner (BWA) (Li & Durbin, 2009). The resulting alignment was pro‐
cessed in the SAM/BAM format using the SAMtools, Picard (https://
broadinstitute.github.io/picard/) and the Genome Analysis Toolkit 
(GATK) in order to correct alignments around indel sites and mark 
potential PCR duplicates (DePristo et al., 2011; McKenna et al., 
2010).
Indel and single‐nucleotide variants were called in the VCF 
format using the Haplotype Caller function of the GATK program. 
Using the VCFhacks package (freely available at https://github.com/
gantzgraf/vcfhacks), variants present in NCBI’s dbSNP147 or the 
Exome Aggregation Consortium database (ExAC; v0.3.1) (Lek et al., 
2016) with a minor allele frequency (MAF) ≥0.1% were excluded. 
Genes known to be associated with autosomal dominant AI were 
then identified from the variants list and segregated with Sanger 
sequencing for all family members for which DNA was available. 
Sanger sequencing was performed using the BigDye Terminator 
v3.1 kit (Life Technologies, Carlsbad, CA, USA) according to man‐
ufacturer’s instructions and resolved on an ABI3130xl sequencer 
(Life Technologies). Results were analysed using SeqScape v2.5 (Life 
Technologies) (Figure 2).
For families 2 and 3, clinical exome libraries were generated 
from genomic DNA from individual II:2 (family 2) and individual II:1 
(family 3) (marked with arrows on the pedigrees, Figure 1). Targeted 
clinical exome sequencing was performed on three micrograms of 
genomic DNA using the Agilent SureSelect Clinical Research Exome 
V1 (Agilent Technologies), according to the manufacturer’s instruc‐
tions. Captured libraries were pooled and sequencing performed on 
an Illumina HiSeq2500 sequencer (Illumina) using rapid mode. The 
resulting fastq files were aligned to the human reference genome 
(GRCh37) using BWA and reads processed using SAMtools, Picard 
and the Genome Analysis Toolkit. Variants within the captured 
regions were called and annotated using AlamutHT (Interactive 
Biosoftware, Rouen, France) and further filtered to identify variants 
within genes known to be associated with amelogenesis imperfecta. 
For family 2, Sanger sequencing to confirm segregation was carried 
out as above (Figure 2).
Primer sequences for Sanger sequencing of both point mutations 
can be found in Supporting Information Table S1. Gene lists used 
for filtering for both families are available in Supporting Information 
Table S2.
Different methods were employed for each family because fam‐
ilies 2 and 3 were part of a pilot study for NHS screening of known 
genes for AI and screened patients from the newly implemented 
NHS screening service, respectively (Holland, 2017). Family 1 were 
recruited as part of ongoing research into the genetic basis of AI, 
based at the Faculty of Medicine and Health, University of Leeds.
2.3 | Hair phenotyping
Samples of hair from family 1 were sectioned perpendicular to the 
shaft using a scalpel and mounted on aluminium stubs. Samples were 
held in place with conductive Acheson Silver DAG 1,415 M paint 
(Agar Scientific, Elektron Technology, Stansted, UK) and sputter 
coated with gold using an auto sputter coater (Agar Scientific). The 
hair was mounted flat (along the longitudinal axis of the shaft) or up‐
right (on the cut end). The hair was imaged using a Hitachi S‐3400N 
scanning electron microscope (Hitachi, Tokyo, Japan), fitted with a 
123 eV Nano XFlash® Detector 5010 (Bruker, Billerica, MA, USA) 
and operated at an accelerating voltage of 5 kV using back‐scatter 
electron detection. One strand of hair from each of the three avail‐
able hair samples was analysed (Figure 3).
2.4 | iTasser
Predicted protein outcome for the missense variant found in family 
2 was assessed using the online protein structure and predictions re‐
source iTasser (Yang & Zhang, 2015). Wild‐type and mutant residues 
F I G U R E  3   Samples of hair from family 
1, imaged longitudinally using Hitachi 
S‐3400N scanning electron microscope 
to investigate differences in hair structure 
between affected and unaffected 
individuals. a = V:2 (affected), b = IV:4 
(affected), c = V:1 (unaffected) normal 
area, d = V:1 (unaffected) irregular area. 
Scale bar = 50 µm
(a) (b)
(c) (d)
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of DLX3 were input and the predicted outcomes for active sites and 
the secondary and tertiary structures of the proteins compared.
3  | RESULTS
One mixed race (family 1—Afro‐Caribbean and Caucasian) British 
family and one Caucasian British family (family 2), both with autoso‐
mal dominantly inherited hypoplastic AI, and one British Caucasian 
individual affected with hypoplastic AI but with no family history 
of AI (family 3) (Figure 1), were recruited to this study as part of a 
larger cohort of AI families. Families 1 and 2 did not display any clini‐
cally obvious co‐segregating health problems, but a kinky, curly hair 
phenotype was reported in family 1. The affected member of fam‐
ily 3 had AI, delayed tooth eruption, taurodontism, kinky/curly hair 
phenotype in early childhood and seizures.
Clinical photographs of affected individual V:2 from family 1 re‐
vealed thin, worn, enamel (Figure 2). The family reported curly, un‐
manageable hair which normalized from adolescence. Taurodontism 
was reported in the clinical records of affected individuals and can 
be seen in the dental panoramic tomograph (DPT) of individual IV:4 
(Supporting Information Figure S1). Clinically evident bony changes 
(e.g., mandibular prognathism, Robinson & Miller, 1966) were not 
reported.
Bitewing radiographs (Supporting Information Figure S1) and 
clinical photographs (Figure 2) for individual III:1 from family 2 ev‐
idence thin, hypoplastic enamel and mild taurodontism of the first 
permanent molars and premature tooth wear. Family 2 reported no 
abnormal hair phenotype. Similar to family 1, no abnormal bone phe‐
notype was reported for family 2, although no specialist radiological 
assessment was undertaken and the alveolar bone on intra‐oral den‐
tal radiographs appeared normal. DNA extracted from the buccal 
swab of individual III:1 was of insufficient quantity for analysis.
Clinical photographs and radiographs from individual II:1, fam‐
ily 3 (Supporting Information Figures S1 and S2) reveal hypoplastic 
enamel and marked taurodontism of both the primary and second‐
ary dentition, with tooth surface loss and caries. No hypodontia was 
reported. Delayed eruption of the upper lateral permanent incisor 
teeth was a feature, along with talon cusps evident on radiography 
on these teeth, but no bony changes were identified in the gnathic 
bones on dental radiographs, nor were they reported by family mem‐
bers. One tooth in the permanent dentition had internal resorption 
and subsequent fracture. A curly/kinky hair phenotype was identi‐
fied in II:1 in early childhood, but this normalized with age and the 
individual’s parents were not aware of a kinky/curly hair phenotype 
in their childhoods.
For all of our families, there was no clinical justification for formal 
bone assessment involving ionizing radiation to confirm or exclude a 
phenotype consistent with TDO.
DNA from individual IV:1 (family 1) was screened by WES. 
Individual II:2 (family 2) and individual II:1 (family 3) were screened 
by targeted clinical exome sequencing. The percentage of bases 
covered at least 15 times for the regions targeted by each capture 
type was 96.8%, 99.5% and 99.0% for individuals IV:1 (family 1), 
individual II:2 (family 2) and individual II:1 (family 3), respectively. 
Since AI in families 1 and 2 displayed a clear dominant inheritance 
pattern, including male‐to‐male transmission, only rare (MAF <0.1%), 
heterozygous, autosomal variants were selected. Variants in genes 
known to be associated with an AI phenotype were prioritized for 
investigation. For family 1, this highlighted a one‐base pair deletion 
in DLX3, c.574delG (NM_005220.2), deleting a base in the third and 
final exon. For family 2, a substitution was identified, c.476G>T; 
p.R159L (NM_005220.2) affecting a base in the second exon of 
the DLX3 transcript. Sanger sequencing confirmed segregation of 
these variants with disease in all available family members (Figure 2). 
Supporting Information Figure S3 shows the Integrated Genomics 
Viewer reads for family 1 to confirm the presence of a 1‐bp deletion 
in clonal sequencing.
The c.574delG variant identified in family 1 is predicted to re‐
sult in a frameshift p.(E192Rfs*66) (NP_005211.1). However, the 
transcript produced is likely to escape nonsense‐mediated decay be‐
cause it is in the final exon (Isken & Maquat, 2008). The variant tran‐
script is predicted to encode a protein of 256 amino acids (compared 
to the 287 amino acid wild‐type protein) with 65 incorrect amino 
acids incorporated at the C‐terminus.
The variant from family 2 incorporates a hydrophobic leucine 
residue instead of a positively charged arginine residue. When the 
p.R159L‐mutated DLX3 protein identified in family 2 was input into 
iTasser, the resultant protein structure was significantly different 
from that predicted for wild‐type DLX3. Protein p.159L is predicted 
to have a more tightly packed arrangement, with additional helical 
regions (Supporting Information Figure S4) and loss of predicted me‐
thionine and propanoic acid ligand‐binding sites.
The c.574delG and c.476G>T variants are absent from databases 
of variation, including NCBI’s dbSNP147, the Exome Variant Server, 
ExAC (v.0.3.1) and gnomAD. The c.574delG and c.476G>T variants 
were assigned a phred‐scaled CADD (v1.3) score of 34 and 35, re‐
spectively, indicating that they are amongst the top 0.04% most pre‐
dicted deleterious variants analysed by CADD (Kircher et al., 2014). 
For the missense variant, c.476G>T, the HumVar‐trained PolyPhen‐2 
model gave a pathogenicity score of 1.0, predicting it to be dam‐
aging, and likely pathogenic (Adzhubei et al., 2010). MutationTaster 
predicted the c.476G>T variant to be disease causing, with a proba‐
bility value of 0.999, again suggesting the missense variant is likely 
pathogenic (Schwarz, Cooper, Schuelke, & Seelow, 2014). The mu‐
tations both affect residues in evolutionarily conserved regions of 
the DLX3 protein sequence (Supporting Information Figure S5), with 
only the African elephant displaying variation at a position equiva‐
lent to p.159 with an alanine residue instead of an arginine residue.
For individual II:1, family 3, a heterozygous deletion of the entire 
coding region of DLX3 was detected by comparative NGS read‐depth 
analysis (Green et al., 2017). After correcting for sample‐to‐sample 
variation in each of the samples in the same sequencing lane (n = 8), 
read depths across DLX3 exons for individual II:1 were compared to 
the median value for the dataset, effectively using the other seven 
sequenced samples in the lane as a control data set for the patient 
     |  187WHITEHOUSE ET al.
sample. Average read‐depth across the DLX3 gene for the eight in‐
dividuals was 1,246×, while the normalized dosage ratios for exons 
1 to 3, respectively, for our patient sample were 0.49, 0.44, 0.47 
(Figure 4), corresponding to a heterozygous deletion of the entire 
gene. This was subsequently confirmed by an NHS clinical labora‐
tory using real‐time PCR with primers mapping within the deleted 
region (data not shown).
Due to the discontiguous nature of clinical exome sequencing, 
the exact breakpoints are unknown. The nearest adjacent loci show‐
ing normal dosage in the patient are at positions chr17:45,924,645 
and chr17:48,263,029 on human genome assembly GRCh37/hg19, 
giving a maximum size of approximately 2.3 Mb, though it is likely 
that the deletion is smaller than this. Deletions including DLX3 were 
not present in ExAC, but a larger deletion also encompassing the 
genes flanking DLX3 was identified in one individual in the Database 
of Genomic Variants (DGV; nsv833474 (MacDonald, Ziman, Yuen, 
Feuk, & Scherer, 2013)). A familial case of TDO with osteogenesis 
imperfecta and intellectual disability has also been reported, as‐
sociated with a heterozygous deletion of 3.4 Mb, including DLX3 
(Harbuz et al., 2013).
The variants from families 1 and 2 were submitted to ClinVar 
(SCV000583455 and SCV000583456) and were entered in the 
Leeds AI Genetics LOVD (http://dna2.leeds.ac.uk/LOVD/).
Hair samples were obtained from three individuals in family 1: 
IV:4, V:2 and V:1 (two affected and one unaffected). These were 
removed directly from the scalp. Analysis revealed a marked differ‐
ence between the affected and unaffected individuals (Figure 3). No 
cuticle was evident for the affected individuals for the hair that was 
analysed. This gave the hair shaft a woody, brittle appearance upon 
imaging by SEM. In comparison, the unaffected family member had 
a largely normal hair shaft, comprised of the typical lamellar cuticle 
scales, with only occasional areas of irregularity in their arrange‐
ment. All of the samples were approximately round in cross section.
4  | DISCUSSION
Here, we report the first families segregating the DLX3 c.574delG, 
p.(E192Rfs*66) or c.476G>T, p.(R159L) variants and give a second 
report of a complete heterozygous deletion of DLX3, found through 
whole‐exome sequencing (family 1) or targeted clinical exome se‐
quencing (families 2 and 3). Figure 5 plots the positions of these 
pathogenic variants in the DLX3 gene and the corresponding pre‐
dicted changes in DLX3 protein. Hypoplastic AI and taurodontism 
were phenotypic features in all families. Brittle, wavy hair changes 
were identified in affected members of family 1, and a kinky/curly 
hair phenotype in childhood was identified in the affected indi‐
vidual in family 3. No abnormal hair phenotype was identified in 
family 2. No bone, nail or skin changes were reported in any of the 
families. Individual II:1 from family 3 was also reported to have 
seizures—a previously unreported finding for TDO. Without know‐
ing the breakpoints of this deletion, it is difficult to know whether 
this phenotype is wholly attributable to the DLX3 deletion, or 
whether other genes flanking DLX3 may have also been deleted. 
DLX3 is known to play a role in craniofacial development and is 
thought to be involved in the development of the ventral forebrain, 
which may explain the seizures (Zhu & Bendall, 2006). However, 
the possibility of involvement of the adjacent genes (e.g., DLX4 or 
F I G U R E  4   Comparative read‐depth analysis of next‐generation 
sequence at the DLX3 locus in family 3. Read depth was corrected 
for sample‐to‐sample variations by dividing the total number of 
reads for each exon in each sample in an NGS lane by the average 
global read‐depth for the sample. That value was then compared 
to the median value for the dataset. Average read‐depth across the 
DLX3 gene for the 8 samples was 1,246×. The normalized dosage 
ratios for exons 1 to 3, respectively, for the patient sample were 
0.49, 0.44, 0.47, implying heterozygous deletion of the entire DLX3 
gene [Colour figure can be viewed at wileyonlinelibrary.com]
F I G U R E  5   Diagrammatic representation of the position of 
reported mutations in DLX3 and the corresponding predicted 
changes in DLX3 (not to scale). Variants marked with + are 
those reported in this paper. c.398G>C, p.(R133P) (Nieminen et 
al., 2011), c.524T>C, p.(I175S) (Mayer et al., 2010), c.533A>G, 
p.(Q178R) (Li et al., 2015), c.545C>T, p.(S182F) (Nieminen et al., 
2011), c.561_562delCT, p.(L187delfs*13) (Dong et al., 2005), 
c.571_574delGGGG, p.(G191Rfs*66) (Price et al., 1998)
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ITGA3) in the resultant phenotype needs to be considered. This 
mutation in DLX3, in contrast to the autosomal dominant muta‐
tions seen in families 1 and 2, may have arisen de novo or could be 
the result of inheritance from one parent, with partial penetrance 
of the phenotype.
The variants discussed in this paper were detected using two 
different methods; for family 1, whole‐exome sequencing was used, 
whilst for families 2 and 3 targeted clinical exome sequencing was 
used. Clinical exome sequencing has the advantages over whole‐
exome sequencing of providing higher coverage for targeted areas, a 
lower cost per sample analysed and easier interpretation. However, 
whole‐exome sequencing allows the identification of variants in new 
genes for AI.
DLX3 is comprised of 3 exons and is located on the long arm of 
chromosome 17, along with other members of the distal‐less family 
of genes (DLX1–6). It is expressed in the placenta and is considered to 
have a pivotal role in hard‐tissue formation, possibly explaining why 
the DLX3 null genotype is fatal in embryo mice (Hwang, Mehrani, 
Millar, & Morasso, 2008; Morasso, Grinberg, Robinson, Sargent, & 
Mahon, 1999). DLX3 is crucial for hair cycling (Hwang et al., 2008), 
patterning of the embryonic ectoderm (Park & Morasso, 2002), and 
is implicated in bone formation (Hassan et al., 2004). It is a transcrip‐
tional activator, expressed in the differentiated epidermal granular 
cell layer and in the matrix cells of hair follicles. It has also recently 
been shown to affect ion transport in amelogenesis through regula‐
tion of genes in the solute carrier (Slc) family (Duverger, Ohara, Bible, 
Zah, & Morasso, 2017).
The phenotype of the affected individuals in all three of our 
families is similar to that seen in TDO, but without clinically obvious 
bony changes, nail features and dermatitis. Conducting bone scans 
and radiographs using ionizing radiation to characterize any bone 
changes could not be justified in the context of the clinical presen‐
tations. The bony changes in TDO are considered to be variable and 
can be difficult to characterize, despite reportedly being present in 
65%–80% of patients (Price et al., 1998). It has also been suggested 
that bony changes progress with age, meaning that while not cur‐
rently clinically apparent, the bony features may be more noticeable 
as the younger affected individuals age (Hart et al., 1997; Price et al., 
1998). The increase in bone density seen in TDO patients has been 
hypothesized to be due to decreased osteoclastic bone due to the 
increased IFN‐γ expression by immune cells, although the pathway is 
not fully elucidated (Choi et al., 2009). It is currently unclear whether 
bones outside of the craniofacial area are also affected in TDO; how‐
ever, Haldeman et al. (2004) demonstrated that bone density was 
increased at the radius and ulna sites in individuals with TDO at ages 
less than 30 years but showed no obvious association between 30 
and 74 years of age. Bone density of the spine and hip was also ele‐
vated in individuals with TDO, even at a young age. One of the more 
common, and easily identifiable, bony features of TDO is mandibu‐
lar prognathism. In a study by Nguyen, Phillips, Frazier‐Bower, and 
Wright (2013), TDO patients were compared to wild‐type controls 
and no mandibular prognathism was identified. However, a retrusive 
maxilla, increased mandibular length and increased ramus height 
were common to most TDO cases, possibly giving the appearance of 
a prognathic mandible in affected individuals.
DLX3 has three main domains: the N‐ and C‐terminus transac‐
tivation domains, and a central homeodomain, encoded by exons 2 
and 3. The homeodomain can interact directly with DNA in a se‐
quence‐specific way and regulates the expression of target genes 
throughout numerous developmental processes (Feledy, Morasso, 
Jang, & Sargent, 1999). All of the previously reported mutations in 
DLX3 (each with an attenuated TDO‐like phenotype) have affected 
residues within, or adjacent to, the homeodomain (Figure 4), altering 
the structure of this region and highlighting its importance in the 
pathogenesis of TDO. The addition of these variants to the exist‐
ing literature highlights the different presentations associated with 
DLX3 variants and demonstrates, for all of our families, a more re‐
stricted phenotype than classical TDO.
The literature around TDO states that the hair of affected indi‐
viduals straightens with age in 54% of affected individuals (Wright 
et al, 1997), and members of family 1 reported that their kinky/curly 
hair phenotype noted in childhood straightened with age. However, 
this changing phenotype does not seem to have been structurally 
demonstrated with SEM imaging of affected individuals from family 
1, as the hair from the affected adult (IV:4) was morphologically simi‐
lar to that from the affected child (V:2), with a woody, brittle appear‐
ance and almost complete lack of cuticle. In the unaffected individual, 
V:1, occasional, patchy, irregular cuticle formation was identified in 
a largely normal shaft. We have no information as to whether indi‐
vidual V:1 had undergone chemical treatments (e.g., straightening or 
colouring), which may have led to damage (Figure 3). The lack of a 
suitable control and the absence of a “hair history” for members of 
family 1 makes associating the DLX3 genotype with the curly/kinky 
hair phenotype, and the structural changes seen with SEM difficult in 
this case. The affected individual from family 3 was reported to have 
a kinky/curly hair in early childhood, but this straightened over time. 
It is difficult to compare our findings to the paper by Wright et al 
(1997) as SEM was not conducted on the hair samples in that cohort. 
It would be advantageous to have hair from family 3 to ascertain any 
structural changes to the hair shaft which may corroborate an ab‐
normal hair phenotype, rather than relying solely on patient reports.
It is unknown whether delayed eruption of the permanent upper 
lateral incisor teeth in family 3 reflects a further phenotypic varia‐
tion in TDO. In a TDO case described by Jain, Kaul, Saha, and Sarkar 
(2017), there was early eruption of the permanent first molar teeth. 
Otherwise, the case had classical features of TDO without a family 
history. The authors suggest the mutation arose sporadically. This 
case was associated with a 4‐bp deletion, but the exact location is 
not discussed in the report. Jain et al. (2017) hypothesized that the 
precocious eruption may be due to increased osteoblastic activity 
around the erupting tooth. As no bony abnormalities were identi‐
fied clinically or on dental radiographs in family 3, it is difficult to 
determine the cause of the delayed eruption for our case. DNA from 
family 3, to confirm the deletion and to determine the exact break‐
points, was unavailable for analysis making comparisons with the 
cases reported by MacDonald et al. (2013) and Harbuz et al. (2013) 
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difficult. It is therefore unknown whether the copy number variant 
identified in the individual from family 3 is the same as those re‐
ported in the literature. Without knowing the exact breakpoints for 
this deletion, pathogenicity is difficult to predict, although disease is 
likely to result from haploinsufficiency. Without genetic testing of 
the parents of individual II:I from family 3, we cannot reliably confirm 
any pattern of inheritance for this variant. Partial penetrance and in‐
heritance of the variant from one of the parents could be causative, 
or the mutation may have arisen de novo.
The mechanism by which DLX3 variants cause disease has 
not been fully elucidated, with numerous mechanisms hypothe‐
sized (Choi et al., 2008; Dong et al., 2005; Duverger et al., 2008, 
2017 ; Feledy et al., 1999). There are conflicting reports suggest‐
ing both haploinsufficiency and a dominant gain‐of‐function effect 
(Duverger et al., 2008; Li & Roberson, 2017; Nieminen et al., 2011). 
Of the DLX3 variants previously reported to date, the c.571_574del‐
GGGG variant is the most similar to the variant reported here in 
family 1. It has been previously shown that the mutant DLX3 pro‐
tein p.(G191Rfs*66) translated from the c.571_574delGGGG tran‐
script is targeted to the nucleus, but unable to bind directly to DNA 
without prior dimerization with a wild‐type protein (Duverger et al., 
2008). This was an unexpected finding as the frameshift would be 
predicted to affect residues downstream of the homeodomain. It 
could be hypothesized that, if produced, the mutant p.(E192Rfs*66) 
protein may be similarly unable to bind to DNA without a wild‐type 
protein partner. Indeed, Li and Roberson (2017) found the transcrip‐
tional activity resulting from the p.(G191Rfs*66) mutant protein was 
comparable to the wild‐type protein, potentially suggesting a dom‐
inant‐negative effect where the mutant protein interferes with the 
normal binding process of the wild‐type protein produced from the 
wild‐type allele. However, the findings of Choi et al. (2008) suggest 
that the p.(G191Rfs*66) protein was able to bind to DNA recognition 
sequences and potentially causes a gain of function due to the novel 
66‐amino acid C‐terminal end, resulting in increased osteoblastic 
activity. Haploinsufficiency has also been discussed by Nieminen et 
al. (2011) as a cause for the phenotypic features seen in individuals 
with the c.571_574delGGGG variant, suggesting the syndromic fea‐
tures of TDO are simply a result of too little wild‐type DLX3 and, 
as such, a reduction in DLX3 activity. The discovery of a heterozy‐
gous deletion of DLX3 in family 3 supports the haploinsufficiency 
mechanism of disease over the dominant‐negative mechanism in 
this family.
The findings of this paper demonstrate the phenotypic spec‐
trum associated with DLX3 variants. Due to the varying functions 
of DLX3 and resultant variable phenotype, it is important for the 
clinician to consider the possibility of syndromic phenotypic features 
when assessing a patient with any of the features of TDO, to ensure 
that other potential features such as atopic dermatitis, delayed tooth 
eruption and pathological bony changes are not overlooked.
This report adds to the variants already reported in genes for 
AI. Such information improves clinical interpretation and allows for 
accurate genetic testing and counselling to be offered to patients 
and their families.
5  | CONCLUSION
DLX3 mutations can be associated with classical TDO or attenuated 
versions of the disease, with varying phenotypes. AI and taurodont‐
ism appear to be universal features across all reported cases with 
an associated clinical impact; nail, hair, bone and skin changes are 
variably reported.
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